Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period of rapid growth fueled by one of the most robust drug development pipelines in oncology. Notably, the biggest driver of market sales growth will be the anticipated approvals of immune checkpoint inhibitors from both multinational corporations as well as domestic developers, poised to transform the current treatment landscape. Biomarker-driven treatments are becoming increasingly attractive, highlighted by the development of Janssen’s Balversa for patients harboring FGFR mutations, and are expected to gain approval within the forecast period, resulting in more therapy options for metastatic patients. Nevertheless, chemotherapies reimbursed through China’s National Reimbursement Drug List will provide the core standard of care for most patients throughout the forecast period.
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other DRG research.
Diagnosed incidence of bladder cancer by disease stage and line of therapy. Clinically and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key bladder cancer regimens through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 11 drugs. Phase II: 7 drugs. Coverage of select early-phase products.